Zimmer Biomet Holdings (ZBH) 130.59 $ZBH
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 130.59 (-0.47), GWPH: 94.07 (-2.04), BAX: 48.48 (-0.02), VASC: 45.35 (-1.10)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Revenue Estimates
Aparajita Dutta - Zacks Investment Research - Thu Jul 28, 7:56AM CDT
Zimmer Biomet's (ZBH) adjusted earnings per share of $2.02 beat this estimate by 3.1%.
ZBH: 130.59 (-0.47)
Zimmer Biomet Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Jul 28, 6:30AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2016. The Company reported second quarter net sales of $1.93 billion, an increase of 65.6% and an increase of 4.5% on an adjusted pro forma, constant currency basis, compared to the second quarter of 2015. Diluted net loss per share for the quarter was $(0.16), compared to a net loss per share of $(1.00) for the prior year period, and adjusted diluted earnings per share for the quarter were $2.02, an increase of 27.8% adjusted over the prior year period.
ZBH: 130.59 (-0.47)
CVS Health (CVS) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:43PM CDT
CVS Health Corporation (CVS) is scheduled to report its second-quarter 2016 results before the opening bell on Aug 2.
ZBH: 130.59 (-0.47), CVS: 98.06 (+4.57), BMY: 75.05 (-1.14), HOLX: 39.03 (+0.05)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.17 (-0.26), ZBH: 130.59 (-0.47), GWPH: 94.07 (-2.04), NUVA: 62.63 (-0.66)
Look at Medical Product Earnings on Jul 28: BSX, RMD & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:59AM CDT
Medical is one of the seven broader sectors among the 16 Zacks sectors to report earnings growth this season.
BSX: 24.17 (-0.26), SRDX: 27.69 (+0.63), ZBH: 130.59 (-0.47), VIVO: 19.29 (-0.26), RMD: 69.38 (-0.47)
Ally Bridge Group Congratulates Medtech SA on its Acquisition by Zimmer Biomet
PR Newswire - Mon Jul 18, 8:35AM CDT
Ally Bridge Group ("ABG"
, a leading China-global cross-border healthcare-focused investment group, is pleased to announce the sale of its entire stake in Medtech SA ("Medtech" or the "Company" to Zimmer Biomet Holdings, Inc. ("Zimmer Biomet", a leading global orthopedics company based in Warsaw, Indiana, USA. Medtech is a surgical robot company headquartered in Montpellier, France, listed on Euronext Paris Stock Exchange with the stock symbol ROSA. Medtech's product portfolio includes two innovative robots for minimally invasive brain and spine procedures ("ROSA Brain" and "ROSA Spine". Both products are FDA approved and CE marked.
ZBH: 130.59 (-0.47)
2016 INVESTIndiana Equity Conference Announces Corporate Presentation Lineup
BusinessWire - Tue Jul 12, 10:00AM CDT
INVESTIndiana, an equity conference that highlights the performance of Indiana public companies, today announced a presentation lineup that features Indiana's top health sciences companies as well as leaders in the banking, energy, high-tech and manufacturing sectors.
ESCA: 10.72 (+0.01), ININ: 56.96 (+5.31), ZBH: 130.59 (-0.47), GABC: 34.26 (-0.03), KBAL: 11.58 (+0.10), HBNC: 27.10 (-0.19), LLY: 83.32 (+0.14), LKFN: 50.80 (-0.43), SRCE: 33.56 (-0.15), ONB: 13.15 (+0.10), ECYT: 3.05 (-0.13), NI: 25.94 (+0.13), INBK: 22.21 (-0.67), BASI: 1.39 (+0.21), MFSF: 28.16 (-0.17)
Zimmer Biomet Announces Live Audio Webcast and Conference Call of Second Quarter 2016 Results
PR Newswire - Mon Jul 11, 3:01PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter 2016 sales and earnings conference call will be broadcast live over the Internet on Thursday, July 28, 2016, at 8 a.m. Eastern Time. A news release detailing the quarterly results will be made available at 7:30 a.m. Eastern Time the morning of the conference call.
ZBH: 130.59 (-0.47)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 45.07 (-0.22), JNJ: 124.85 (-0.55), ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02), MDT: 87.64 (-0.42), TMO: 156.44 (-3.12), STJ: 83.52 (-0.21), HTWR: 57.89 (-0.07), XRAY: 64.63 (+0.40), NUVA: 62.63 (-0.66), FEIC: 106.65 (+0.20)
Zimmer Biomet Poised on LDR Inclusion, Product Launches
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:12AM CDT
On Jul 4, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
BSX: 24.17 (-0.26), ICUI: 116.02 (-1.05), ZBH: 130.59 (-0.47), NUVA: 62.63 (-0.66)
Zimmer Biomet Announces Enhancements to Joint Reconstruction Portfolio for the Treatment of Patients with Significant Bone Loss
PR Newswire - Thu Jun 16, 3:30PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the global commercial launch of new enhancements to its OSS(TM) Orthopedic Salvage System, a comprehensive set of joint reconstruction prostheses designed to treat patients suffering from bone loss due to tumor resection, ligamentous deficiencies, orthopaedic trauma or patients who have undergone multiple knee and hip revision arthroplasties.
ZBH: 130.59 (-0.47)
LDR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of LDR Holding Corporation (LDRH) Over the Proposed Sale of the Company to Zimmer Biomet Holdings, Inc.
PR Newswire - Wed Jun 15, 10:18AM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of LDR Holding Corporation ("LDR" or the "Company" (NASDAQ:LDRH) for potential breaches of fiduciary duties in connection with the sale of the Company to Zimmer Biomet Holdings, Inc. for approximately $1.0 billion.
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into the Fairness of the Sale of LDR Holding Corporation to Zimmer Biomet Holdings, Inc. - LDRH
PR Newswire - Thu Jun 09, 10:20AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
LDR (LDRH) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of LDR Holding Corporation; Is $37.00 a Fair Price?
PR Newswire - Wed Jun 08, 7:14PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of LDR Holding Corporation (NASDAQ: LDRH) breached their fiduciary duties in connection with the proposed sale of the Company to Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
Zimmer Biomet's Spine Business to Get a Boost with LDR Buy
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:00AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire LDR Holding Corp. (LDRH) for a total deal value of $1 billion.
BSX: 24.17 (-0.26), ICUI: 116.02 (-1.05), ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of LDR Holding Corporation to Zimmer Biomet Holdings, Inc. - LDRH
ACCESSWIRE - Tue Jun 07, 10:19AM CDT
NEW YORK, NY / ACCESSWIRE / June 7, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
LDR HOLDING CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
BusinessWire - Tue Jun 07, 9:28AM CDT
Rigrodsky & Long, P.A.:
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
Zimmer buying LDR for $1 billion
AP - Tue Jun 07, 8:04AM CDT
NEW YORK (AP) — Zimmer Biomet will spend $1 billion to acquire medical device maker buy LDR Holding Corp., strengthening its position in the spine disorder surgical technology business.
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
LDR (LDRH) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of LDR Holding Corporation; Are Shareholders Getting a Fair Price?
PR Newswire - Tue Jun 07, 7:13AM CDT
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of LDR Holding Corporation (NASDAQ: LDRH) breached their fiduciary duties in connection with the proposed sale of the Company to Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 130.59 (-0.47), GWPH: 94.07 (-2.04), BAX: 48.48 (-0.02), VASC: 45.35 (-1.10)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Revenue Estimates
Aparajita Dutta - Zacks Investment Research - Thu Jul 28, 7:56AM CDT
Zimmer Biomet's (ZBH) adjusted earnings per share of $2.02 beat this estimate by 3.1%.
ZBH: 130.59 (-0.47)
Zimmer Biomet Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Jul 28, 6:30AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2016. The Company reported second quarter net sales of $1.93 billion, an increase of 65.6% and an increase of 4.5% on an adjusted pro forma, constant currency basis, compared to the second quarter of 2015. Diluted net loss per share for the quarter was $(0.16), compared to a net loss per share of $(1.00) for the prior year period, and adjusted diluted earnings per share for the quarter were $2.02, an increase of 27.8% adjusted over the prior year period.
ZBH: 130.59 (-0.47)
CVS Health (CVS) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:43PM CDT
CVS Health Corporation (CVS) is scheduled to report its second-quarter 2016 results before the opening bell on Aug 2.
ZBH: 130.59 (-0.47), CVS: 98.06 (+4.57), BMY: 75.05 (-1.14), HOLX: 39.03 (+0.05)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.17 (-0.26), ZBH: 130.59 (-0.47), GWPH: 94.07 (-2.04), NUVA: 62.63 (-0.66)
Look at Medical Product Earnings on Jul 28: BSX, RMD & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:59AM CDT
Medical is one of the seven broader sectors among the 16 Zacks sectors to report earnings growth this season.
BSX: 24.17 (-0.26), SRDX: 27.69 (+0.63), ZBH: 130.59 (-0.47), VIVO: 19.29 (-0.26), RMD: 69.38 (-0.47)
Ally Bridge Group Congratulates Medtech SA on its Acquisition by Zimmer Biomet
PR Newswire - Mon Jul 18, 8:35AM CDT
Ally Bridge Group ("ABG"
, a leading China-global cross-border healthcare-focused investment group, is pleased to announce the sale of its entire stake in Medtech SA ("Medtech" or the "Company" to Zimmer Biomet Holdings, Inc. ("Zimmer Biomet", a leading global orthopedics company based in Warsaw, Indiana, USA. Medtech is a surgical robot company headquartered in Montpellier, France, listed on Euronext Paris Stock Exchange with the stock symbol ROSA. Medtech's product portfolio includes two innovative robots for minimally invasive brain and spine procedures ("ROSA Brain" and "ROSA Spine". Both products are FDA approved and CE marked. ZBH: 130.59 (-0.47)
2016 INVESTIndiana Equity Conference Announces Corporate Presentation Lineup
BusinessWire - Tue Jul 12, 10:00AM CDT
INVESTIndiana, an equity conference that highlights the performance of Indiana public companies, today announced a presentation lineup that features Indiana's top health sciences companies as well as leaders in the banking, energy, high-tech and manufacturing sectors.
ESCA: 10.72 (+0.01), ININ: 56.96 (+5.31), ZBH: 130.59 (-0.47), GABC: 34.26 (-0.03), KBAL: 11.58 (+0.10), HBNC: 27.10 (-0.19), LLY: 83.32 (+0.14), LKFN: 50.80 (-0.43), SRCE: 33.56 (-0.15), ONB: 13.15 (+0.10), ECYT: 3.05 (-0.13), NI: 25.94 (+0.13), INBK: 22.21 (-0.67), BASI: 1.39 (+0.21), MFSF: 28.16 (-0.17)
Zimmer Biomet Announces Live Audio Webcast and Conference Call of Second Quarter 2016 Results
PR Newswire - Mon Jul 11, 3:01PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter 2016 sales and earnings conference call will be broadcast live over the Internet on Thursday, July 28, 2016, at 8 a.m. Eastern Time. A news release detailing the quarterly results will be made available at 7:30 a.m. Eastern Time the morning of the conference call.
ZBH: 130.59 (-0.47)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 45.07 (-0.22), JNJ: 124.85 (-0.55), ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02), MDT: 87.64 (-0.42), TMO: 156.44 (-3.12), STJ: 83.52 (-0.21), HTWR: 57.89 (-0.07), XRAY: 64.63 (+0.40), NUVA: 62.63 (-0.66), FEIC: 106.65 (+0.20)
Zimmer Biomet Poised on LDR Inclusion, Product Launches
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:12AM CDT
On Jul 4, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
BSX: 24.17 (-0.26), ICUI: 116.02 (-1.05), ZBH: 130.59 (-0.47), NUVA: 62.63 (-0.66)
Zimmer Biomet Announces Enhancements to Joint Reconstruction Portfolio for the Treatment of Patients with Significant Bone Loss
PR Newswire - Thu Jun 16, 3:30PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the global commercial launch of new enhancements to its OSS(TM) Orthopedic Salvage System, a comprehensive set of joint reconstruction prostheses designed to treat patients suffering from bone loss due to tumor resection, ligamentous deficiencies, orthopaedic trauma or patients who have undergone multiple knee and hip revision arthroplasties.
ZBH: 130.59 (-0.47)
LDR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of LDR Holding Corporation (LDRH) Over the Proposed Sale of the Company to Zimmer Biomet Holdings, Inc.
PR Newswire - Wed Jun 15, 10:18AM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of LDR Holding Corporation ("LDR" or the "Company"
(NASDAQ:LDRH) for potential breaches of fiduciary duties in connection with the sale of the Company to Zimmer Biomet Holdings, Inc. for approximately $1.0 billion. ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into the Fairness of the Sale of LDR Holding Corporation to Zimmer Biomet Holdings, Inc. - LDRH
PR Newswire - Thu Jun 09, 10:20AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
LDR (LDRH) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of LDR Holding Corporation; Is $37.00 a Fair Price?
PR Newswire - Wed Jun 08, 7:14PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of LDR Holding Corporation (NASDAQ: LDRH) breached their fiduciary duties in connection with the proposed sale of the Company to Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
Zimmer Biomet's Spine Business to Get a Boost with LDR Buy
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:00AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire LDR Holding Corp. (LDRH) for a total deal value of $1 billion.
BSX: 24.17 (-0.26), ICUI: 116.02 (-1.05), ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of LDR Holding Corporation to Zimmer Biomet Holdings, Inc. - LDRH
ACCESSWIRE - Tue Jun 07, 10:19AM CDT
NEW YORK, NY / ACCESSWIRE / June 7, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
LDR HOLDING CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
BusinessWire - Tue Jun 07, 9:28AM CDT
Rigrodsky & Long, P.A.:
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
Zimmer buying LDR for $1 billion
AP - Tue Jun 07, 8:04AM CDT
NEW YORK (AP) — Zimmer Biomet will spend $1 billion to acquire medical device maker buy LDR Holding Corp., strengthening its position in the spine disorder surgical technology business.
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
LDR (LDRH) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of LDR Holding Corporation; Are Shareholders Getting a Fair Price?
PR Newswire - Tue Jun 07, 7:13AM CDT
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of LDR Holding Corporation (NASDAQ: LDRH) breached their fiduciary duties in connection with the proposed sale of the Company to Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
ZBH: 130.59 (-0.47), LDRH: 36.98 (-0.02)
